• By Madura Jayatunga, Lotte Bruens, Ludwig Ruder, Ulrik Schulze, Christoph Meier
AI is beginning to transform biologics discovery. The power of algorithms used in biologics discovery has increased over the last decade, and today between 50 and 60 AI-enabled biologics are in different stages of discovery, preclinical and clinical development. We expect the number of AI-enabled biologics to continue to grow rapidly, driven by advances in AI technology and algorithms, growing computing power, increasing availability of data, and evolving discovery workflows. We show that the volume of data used for training algorithms in biologics discovery is increasing exponentially over time, a trend reminiscent of Moore’s Law in computer technology.
• Source: Shutterstock
Artificial intelligence (AI) and machine learning are revolutionizing drug discovery. Over the last five to ten years the main focus has been on small molecules, where we are seeing strong growth in the number of compounds discovered using AI technologies.
In parallel, but less well-known, AI is beginning to transform other areas of drug discovery, most importantly biologics (protein and peptide-based medicines). Over the past decade many AI algorithms and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
